Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions

por Yardley, Denise A.
Publicado 2013

Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes

por Yardley, Denise A.
Publicado 2013

Taxanes in the elderly patient with metastatic breast cancer

por Yardley, Denise A
Publicado 2015

Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer

por Yardley, Denise A
Publicado 2016

Healthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents

por Meyer, Nicole, Hao, Yanni, Song, Xue, Shi, Nianwen, Johnson, William, Willemann Rogerio, Jaqueline, Yardley, Denise A.
Publicado 2014

First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial

por Liu, Minetta C, Janni, Wolfgang, Georgoulias, Vassilis, Yardley, Denise A, Harbeck, Nadia, Wei, Xin, McGovern, Desmond, Beck, Robert
Publicado 2019

Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer

por Yardley, Denise A., Kaufman, Peter A., Brufsky, Adam, Yood, Marianne Ulcickas, Rugo, Hope, Mayer, Musa, Quah, Cheng, Yoo, Bongin, Tripathy, Debu
Publicado 2014

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer

por Rugo, Hope S., Brufsky, Adam M., Yood, Marianne Ulcickas, Tripathy, Debu, Kaufman, Peter A., Mayer, Musa, Yoo, Bongin, Abidoye, Oyewale O., Yardley, Denise A.
Publicado 2013

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study

por Kaufman, Peter A., Brufsky, Adam M., Mayer, Musa, Rugo, Hope S., Tripathy, Debu, Yood, Marianne Ulcickas, Feng, Shibao, Wang, Lisa I., Quah, Cheng S., Yardley, Denise A.
Publicado 2012

Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherap...

por Yardley, Denise A., Hart, Lowell, Bosserman, Linda, Salleh, Mansoor N., Waterhouse, David M., Hagan, Maura K., Richards, Paul, DeSilvio, Michelle L., Mahoney, Janine M., Nagarwala, Yasir
Publicado 2012

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve,...

por Miller, Kathy, Cortes, Javier, Hurvitz, Sara A., Krop, Ian E., Tripathy, Debu, Verma, Sunil, Riahi, Kaveh, Reynolds, Joseph G., Wickham, Thomas J., Molnar, Istvan, Yardley, Denise A.
Publicado 2016

De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry

por Tripathy, Debu, Brufsky, Adam, Cobleigh, Melody, Jahanzeb, Mohammad, Kaufman, Peter A., Mason, Ginny, O'Shaughnessy, Joyce, Rugo, Hope S., Swain, Sandra M., Yardley, Denise A., Chu, Laura, Li, Haocheng, Antao, Vincent, Hurvitz, Sara A.
Publicado 2019

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer...

por Yardley, Denise A., Brufsky, Adam, Coleman, Robert E., Conte, Pierfranco F., Cortes, Javier, Glück, Stefan, Nabholtz, Jean-Mark A., O’Shaughnessy, Joyce, Beck, Robert M., Ko, Amy, Renschler, Markus F., Barton, Debora, Harbeck, Nadia
Publicado 2015

Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative b...

por Yardley, Denise A., Brufsky, Adam, Coleman, Robert E., Conte, Pierfranco F., Cortes, Javier, Glück, Stefan, Nabholtz, Jean-Mark A., O’Shaughnessy, Joyce, Beck, Robert M., Ko, Amy, Renschler, Markus F., Barton, Debora, Harbeck, Nadia
Publicado 2016

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer

por Kaufman, Peter A, Bloom, Kenneth J, Burris, Howard, Gralow, Julie R, Mayer, Musa, Pegram, Mark, Rugo, Hope S, Swain, Sandra M, Yardley, Denise A, Chau, Miu, Lalla, Deepa, Yoo, Bongin, Brammer, Melissa G, Vogel, Charles L
Publicado 2014

Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study

por Vahdat, Linda T., Schmid, Peter, Forero-Torres, Andres, Blackwell, Kimberly, Telli, Melinda L., Melisko, Michelle, Möbus, Volker, Cortes, Javier, Montero, Alberto J., Ma, Cynthia, Nanda, Rita, Wright, Gail S., He, Yi, Hawthorne, Thomas, Bagley, Rebecca G., Halim, Abdel-Baset, Turner, Christopher D., Yardley, Denise A.
Publicado 2021

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1

por Rugo, Hope S., Dieras, Veronique, Cortes, Javier, Patt, Debra, Wildiers, Hans, O’Shaughnessy, Joyce, Zamora, Esther, Yardley, Denise A., Carter, Gebra Cuyun, Sheffield, Kristin M., Li, Li, Andre, Valerie A. M., Li, Xiaohong I., Frenzel, Martin, Huang, Yu-Jing, Dickler, Maura N., Tolaney, Sara M.
Publicado 2020

Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

por Yardley, Denise A., Noguchi, Shinzaburo, Pritchard, Kathleen I., Burris, Howard A., Baselga, José, Gnant, Michael, Hortobagyi, Gabriel N., Campone, Mario, Pistilli, Barbara, Piccart, Martine, Melichar, Bohuslav, Petrakova, Katarina, Arena, Francis P., Erdkamp, Frans, Harb, Wael A., Feng, Wentao, Cahana, Ayelet, Taran, Tetiana, Lebwohl, David, Rugo, Hope S.
Publicado 2013

Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

por Yardley, Denise A., Noguchi, Shinzaburo, Pritchard, Kathleen I., Burris, Howard A., Baselga, José, Gnant, Michael, Hortobagyi, Gabriel N., Campone, Mario, Pistilli, Barbara, Piccart, Martine, Melichar, Bohuslav, Petrakova, Katarina, Arena, Francis P., Erdkamp, Frans, Harb, Wael A., Feng, Wentao, Cahana, Ayelet, Taran, Tetiana, Lebwohl, David, Rugo, Hope S.
Publicado 2014

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial

por Cortés, Javier, Rugo, Hope S., Awada, Ahmad, Twelves, Chris, Perez, Edith A., Im, Seock–Ah, Gómez-Pardo, Patricia, Schwartzberg, Lee S., Diéras, Veronique, Yardley, Denise A., Potter, David A., Mailliez, Audrey, Moreno-Aspitia, Alvaro, Ahn, Jin-Seok, Zhao, Carol, Hoch, Ute, Tagliaferri, Mary, Hannah, Alison L., O’Shaughnessy, Joyce
Publicado 2017